An adhesive oral disc for sustained release of cannabinoids is presented. The disc includes one or more cannabinoids and is composed of at least a mucosal contacting layer having a mucosal contacting surface operable to be fixed to the gingiva of a person in need of alleviation or treatment of a medical condition, where the mucosal contacting layer includes one or more mucoadhesive polymers allowing the adhesive oral disc to adhere to the gingiva for an extended period of time. Further, the disc includes a non-mucoadhesive module fused to the mucosal contacting layer, where the non-mucoadhesive module includes a solid tablet composition allowing the non-mucoadhesive module to dissolve within an extended period of time upon adhesion of the adhesive oral disc to the gingiva. The invention is particularly useful for alleviation or treatment of ulcers.
A dissolvable orally adhering tablet for sustained release is disclosed, the tablet comprising an active ingredient, wherein the tablet is a multilayer tablet comprising a first layer and a second layer, the first layer being a mucoadhesive layer comprising a natural gum mucoadhesive and the second layer comprising at least one sugar alcohol.
A mouthwash and method for oral care benefits includes a swishable powder delivery system having a content of at least two types of sugar alcohol particles with different particle size distributions and one or more active ingredients, the powder delivery system being a dry and flowable population of particles suitable for resembling a liquid mouthwash by swishing the powder delivery system, thereby generating fluid in the oral cavity without adding water.
A61K 8/49 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques contenant des composés hétérocycliques
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/191 - Acides acycliques ayant plusieurs groupes hydroxyle, p.ex. acide gluconique
A61K 31/194 - Acides carboxyliques, p.ex. acide valproïque ayant plusieurs groupes carboxyle, p.ex. acides succinique, maléique ou phtalique
A dissolvable orally adhering nicotine tablet for sustained delivery of nicotine is disclosed, the tablet is a multilayer tablet comprising a first layer and a second layer, wherein the first layer is a mucoadhesive layer comprising a mucoadhesive, and wherein the second layer comprises at least one sugar alcohol and nicotine.
A dissolvable orally adhering nicotine tablet for sustained delivery of nicotine is disclosed, the tablet is a multilayer tablet comprising a first layer and a second layer, wherein the first layer is a mucoadhesive layer comprising a mucoadhesive, nicotine, and at least one sugar alcohol, and wherein the second layer comprises at least one sugar alcohol.
The invention relates an oral tablet suitable for active pharmaceutical ingredients comprising an intragranular portion and an extragranular portion. The intragranular portion comprising a plurality of granules each comprising one or more active pharmaceutical ingredients; one or more binders; and one or more excipients comprising one or more sweeteners in an amount of at least 20% by weight of the plurality of granules. The extragranular portion comprising a population of particles comprising non-directly compressible (non-DC) sweetener particles, the non-DC sweetener particles having not been granulated prior to tableting and providing the oral tablet with a plurality of discrete non-DC areas evenly distributed in the oral tablet or at least one module of the oral tablet.
A61K 31/167 - Amides, p.ex. acides hydroxamiques ayant des cycles aromatiques, p.ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p.ex. lidocaïne, paracétamol
A61K 31/485 - Dérivés du morphinane, p.ex. morphine, codéine
An orally dissolvable or chewable tableted powder formulation is presented. The formulation includes one or more carrier systems including one or more liquid or solid self-emulsifying systems loaded with cannabinoids in an amount of at least 10% by weight of the tableted powder formulation. The one or more self-emulsifying systems includes: at least one or more surfactants, one or more lipids and one or more isolated or synthetic cannabinoids when the self-emulsifying system is a liquid self-emulsifying system, and at least one or more surfactants, one or more waxes and one or more isolated or synthetic cannabinoids when the self-emulsifying system is a solid self-emulsifying system. The formulation further includes one or more water-soluble agents in an amount of 20-80% by weight of the tableted powder formulation and one or more flavors.
A61K 47/14 - Esters d’acides carboxyliques, p.ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/26 - Hydrates de carbone, p.ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharides; Leurs dérivés, p.ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes ; Huiles, graisses ou cires naturelles ou naturelles modifiées, p.ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
An orally dissolvable or chewable tableted powder formulation, includes one or more mesoporous silica carriers loaded with a liquid cannabinoid suspension or solution; one or more water-soluble agents in an amount of 20-80% by weight of the tableted powder formulation; and one or more flavors, wherein the liquid cannabinoid suspension or solution includes one or more cannabinoids and one or more non-volatile solvents in a weight ratio of cannabinoid to solvent of 10:1 to 1:10.
Disclosed is an oral nicotine pouch composition comprising nicotine, water in an amount of at least 5% by weight of the pouch composition, alginate, inorganic divalent cations, and at least one pH regulating agent comprising inorganic phosphate. Also disclosed is an oral nicotine pouch composition comprising inorganic multivalent cations and a pouched product.
An orally dissolvable or chewable tableted powder formulation is presented. The formulation includes one or more carrier systems including one or more liquid or solid self-emulsifying systems loaded with cannabinoids in an amount of at least 10% by weight of the tableted powder formulation. The one or more self-emulsifying systems includes: at least one or more surfactants, one or more lipids and one or more isolated or synthetic cannabinoids when self-emulsifying system is a liquid self-emulsifying system, and at least one or more surfactants, one or more waxes and one or more isolated or synthetic cannabinoids when self-emulsifying system is a solid self-emulsifying system. The formulation further includes one or more water-soluble agents in an amount of 20-80% by weight of the tableted powder formulation and one or more flavors. The one or more surfactants includes one or more surfactants having a chemical structure that includes a polyethylene glycol moiety.
A61K 47/10 - Alcools; Phénols; Leurs sels, p.ex. glycérol; Polyéthylène glycols [PEG]; Poloxamères; Alkyléthers de PEG/POE
A61K 47/14 - Esters d’acides carboxyliques, p.ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes ; Huiles, graisses ou cires naturelles ou naturelles modifiées, p.ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
The present invention relates to an orally dissolvable or chewable tableted powder formulation. The formulation comprising one or more carrier systems comprising one or more liquid or solid self-emulsifying systems loaded with cannabinoids in an amount of at least 10% by weight of the tableted powder formulation; the one or more self-emulsifying systems including: i) at least one or more surfactants, one or more lipids and one or more isolated or synthetic cannabinoids when the self-emulsifying system is a liquid self-emulsifying system, and ii) at least one or more surfactants, one or more waxes and one or more isolated or synthetic cannabinoids when the self-emulsifying system is a solid self-emulsifying system. The formulation further including one or more water-soluble agents in an amount of 20-80% by weight of the tableted powder formulation and one or more flavors. The one or more surfactants comprises one or more surfactants having a chemical structure that includes a polyethylene glycol (PEG) moiety.
The present invention relates to an orally dissolvable or chewable tableted powder formulation. The formulation comprising one or more carrier systems comprising one or more liquid or solid self-emulsifying systems loaded with cannabinoids in an amount of at least 10% by weight of the tableted powder formulation; the one or more self-emulsifying systems including: i) at least one or more surfactants, one or more lipids and one or more isolated or synthetic cannabinoids when the self- emulsifying system is a liquid self-emulsifying system, and ii) at least one or more surfactants, one or more waxes and one or more isolated or synthetic cannabinoids when the self-emulsifying system is a solid self-emulsifying system. The formulation further including one or more water-soluble agents in an amount of 20-80% by weight of the tableted powder formulation and one or more flavors.
The present invention relates to an orally dissolvable or chewable tableted powder formulation, comprising one or more mesoporous silica carriers loaded with a liquid cannabinoid suspension or solution; one or more water-soluble agents in an amount of 20-80% by weight of the tableted powder formulation; and one or more flavors, wherein the liquid cannabinoid suspension or solution comprises one or more cannabinoids and one or more non-volatile solvents in a weight ratio of cannabinoid to solvent of 10:1 to 1:10.
The invention relates to an orally disintegrating nicotine tablet for nicotine craving relief comprising a pressed powder formulation, the tablet being designed to disintegrate within a period of less than 60 seconds upon oral administration, the powder formulation comprising an amount of nicotine and a pH regulating agent.
A nicotine pouched product is disclosed, the pouched product comprising a pouch composition and a saliva-permeable pouch enclosing said pouch composition, the pouch composition comprising nicotine and a pouch substrate, the pouch substrate comprising water-insoluble fiber, wherein said pouch composition comprises nicotine in an amount of at least 0.25% by weight of the pouch composition, and wherein the pouched product comprises said pouch composition in an amount of no more than 400 mg.
A nicotine pouch composition is disclosed, the composition comprising nicotine, water-insoluble fibers, and a particulate inert filler, wherein the pouch composition comprises said inert filler in an amount of at least 5% by weight of the pouch composition, wherein the pouch composition further comprises at least 10% by weight of water. Also, a pouched product is disclosed.
A dissolvable orally adhering tablet for sustained release is disclosed, the tablet comprising an active ingredient, wherein the tablet is a multilayer tablet comprising a first layer and a second layer, the first layer being a mucoadhesive layer comprising a natural gum mucoadhesive and the second layer comprising at least one sugar alcohol.
A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
A61K 31/444 - Pyridines non condensées; Leurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p.ex. amrinone
A dissolvable orally adhering nicotine tablet for sustained delivery of nicotine is disclosed, the tablet is a multilayer tablet comprising a first layer and a second layer, wherein the first layer is a mucoadhesive layer comprising a mucoadhesive, nicotine, and at least one sugar alcohol, and wherein the second layer comprises at least one sugar alcohol.
A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
A61K 31/444 - Pyridines non condensées; Leurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p.ex. amrinone
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p.ex. sulpiride, succinimide, tolmétine, buflomédil
A61K 31/46 - Aza-8-bicyclo[3.2.1]octane; Ses dérivés, p.ex. atropine, cocaïne
19.
AN ADHESIVE ORAL DISC FOR SUSTAINED RELEASE OF CANNABINOIDS
The present invention relates to an adhesive oral disc for sustained release of cannabinoids. The disc comprises one or more cannabinoids and being composed of at least a mucosal contacting layer having a mucosal contacting surface operable to be 5 fixed to the gingiva of a person in need of alleviation or treatment of a medical condition, where the mucosal contacting layer comprising one or more mucoadhesive polymers allowing the adhesive oral disc to adhere to the gingiva for an extended period of time. Further, the disc comprises a non-mucoadhesive module fused to the mucosal contacting layer, where the non-mucoadhesive module comprising a solid 10 tablet composition allowing the non-mucoadhesive module to dissolve within an extended period of time upon adhesion of the adhesive oral disc to the gingiva. The invention is particularly useful for alleviation or treatment of ulcers.
A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
A61K 31/444 - Pyridines non condensées; Leurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p.ex. amrinone
The invention relates to a powder premixture for oral administration of cannabinoids, comprising a cannabinoid powder composition comprising one or more isolated cannabinoids in an amount of at least 2% by weight of the powder premixture; a lipid composition comprising one or more triglycerides in an amount of at least 1.0% by weight of the powder premixture; and a sweetener powder composition comprising one or more sweeteners, wherein the weight ratio between the one or more triglycerides and the one or more sweeteners is in the range of 1:50 to 1:4.
A23L 29/30 - Aliments ou produits alimentaires contenant des additifs; Leur préparation ou leur traitement contenant des hydrolysats d'amidon, p.ex. de la dextrine
A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
A23L 27/30 - ALIMENTS, PRODUITS ALIMENTAIRES OU BOISSONS NON ALCOOLISÉES NON COUVERTS PAR LES SOUS-CLASSES OU ; LEUR PRÉPARATION OU TRAITEMENT, p.ex. CUISSON, MODIFICATION DES QUALITÉS NUTRITIVES, TRAITEMENT PHYSIQUE ; CONSERVATION DES ALIMENTS OU PRODUITS ALIMENTAIRES EN GÉNÉRAL Édulcorants artificiels; Sels de table; Substituts diététiques du sel; Leur préparation ou leur traitement Édulcorants artificiels
The invention relates to a powder premixture for oral administration of cannabinoids, comprising a cannabinoid powder composition comprising one or more isolated cannabinoids in an amount of at least 2% by weight of the powder premixture; a lipid 5 composition comprising one or more triglycerides in an amount of at least 1.0% by weight of the powder premixture; and a sweetener powder composition comprising one or more sweeteners, wherein the weight ratio between the one or more triglycerides and the one or more sweeteners is in the range of 1:50 to 1:1. 10
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p.ex. cannabinols, méthanthéline
A61K 47/14 - Esters d’acides carboxyliques, p.ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 9/68 - Préparations médicinales caractérisées par un aspect particulier du type chewing-gum
The invention relates to a powder premixture for oral administration of cannabinoids, comprising a cannabinoid powder composition comprising one or more isolated cannabinoids in an amount of at least 2% by weight of the powder premixture; a lipid composition comprising one or more triglycerides in an amount of at least 1.0% by weight of the powder premixture; and a sweetener powder composition comprising one or more sweeteners, wherein the weight ratio between the one or more triglycerides and the one or more sweeteners is in the range of 1:50 to 1:4.
A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
A23L 27/00 - ALIMENTS, PRODUITS ALIMENTAIRES OU BOISSONS NON ALCOOLISÉES NON COUVERTS PAR LES SOUS-CLASSES OU ; LEUR PRÉPARATION OU TRAITEMENT, p.ex. CUISSON, MODIFICATION DES QUALITÉS NUTRITIVES, TRAITEMENT PHYSIQUE ; CONSERVATION DES ALIMENTS OU PRODUITS ALIMENTAIRES EN GÉNÉRAL Édulcorants artificiels; Sels de table; Substituts diététiques du sel; Leur préparation ou leur traitement
A23L 27/30 - ALIMENTS, PRODUITS ALIMENTAIRES OU BOISSONS NON ALCOOLISÉES NON COUVERTS PAR LES SOUS-CLASSES OU ; LEUR PRÉPARATION OU TRAITEMENT, p.ex. CUISSON, MODIFICATION DES QUALITÉS NUTRITIVES, TRAITEMENT PHYSIQUE ; CONSERVATION DES ALIMENTS OU PRODUITS ALIMENTAIRES EN GÉNÉRAL Édulcorants artificiels; Sels de table; Substituts diététiques du sel; Leur préparation ou leur traitement Édulcorants artificiels
A23L 33/10 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement en utilisant des additifs
A23L 33/115 - Acides gras ou leurs dérivés; Graisses ou huiles
A23P 10/28 - Mise en comprimés; Fabrication de produits alimentaires en barres par compression d’un mélange pulvérulent sec
A23P 10/40 - Fabrication de poudres à écoulement libre ou instantanées, c. à. d. de poudres reconstituées rapidement par l’ajout d’un liquide
A23G 3/36 - Sucreries, confiseries ou massepain; Procédés pour leur fabrication caractérisés par la composition
A23G 3/48 - Sucreries, confiseries ou massepain; Procédés pour leur fabrication caractérisés par la composition contenant des végétaux ou des parties de ceux-ci, p.ex. des fruits, des graines, des extraits
A23G 4/06 - Chewing-gum caractérisé par la composition
A23G 4/12 - Chewing-gum caractérisé par la composition contenant des agents paramédicaux ou diététiques, p.ex. des vitamines
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p.ex. cannabinols, méthanthéline
A61K 47/10 - Alcools; Phénols; Leurs sels, p.ex. glycérol; Polyéthylène glycols [PEG]; Poloxamères; Alkyléthers de PEG/POE
A61K 47/14 - Esters d’acides carboxyliques, p.ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A water-dissolvable compressed oral nicotine lozenge is disclosed, the oral nicotine lozenge comprising a first module and a second module, the first and the second modules being fused by compression, the first module being a lozenge module comprising at least one sugar alcohol and the second module being an FDT-module comprising at least one sugar alcohol and nicotine. Also, a method of manufacturing a water-dissolvable compressed oral nicotine lozenge is disclosed.
A61K 47/26 - Hydrates de carbone, p.ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharides; Leurs dérivés, p.ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. carbomères
24.
FLOWPACK WITH COMPOSITION FOR IMPROVED TASTE MASKING OF ACTIVES
The present invention relates to a new powder delivery system that is not in tablet form but contained in a flowpack. In particular, there is provided a flowpack for oral delivery of active pharmaceutical ingredients comprising a flowable population of particles including different types of particles where the particles comprise a first type of particles comprising one or more distinct portions of particles with a content of one or more active pharmaceutical ingredients and a carrier for the one or more active pharmaceutical ingredients, a second type of particles in an amount of 30-95% by weight of the population of particles separate from the first type of particles, the second type of particles comprising at least 95% by weight of one or more sweeteners, and a third type of particles in an amount of 1-10% by weight of the population of particles separate from the first and second type of particles, the third type of particles comprising flavor.
A61K 47/26 - Hydrates de carbone, p.ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharides; Leurs dérivés, p.ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 31/167 - Amides, p.ex. acides hydroxamiques ayant des cycles aromatiques, p.ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p.ex. lidocaïne, paracétamol
A61K 31/485 - Dérivés du morphinane, p.ex. morphine, codéine
A water-dissolvable nicotine tablet is disclosed, the nicotine tablet comprising at least a first compressed module and a second compressed module, wherein the first compressed module is an FDT-module and comprises nicotine, alkaline pH regulating agent, and disintegrant, and, wherein the second compressed module is a lozenge-module and comprises acidic pH regulating agent. Also, a method of manufacturing a nicotine tablet is disclosed.
A61K 31/4439 - Pyridines non condensées; Leurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p.ex. oméprazole
05 - Produits pharmaceutiques, vétérinaires et hygièniques
40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Pharmaceutical preparations, namely, smoking cessation preparations, analgesic preparations, sleep aid- preparations, anti-pyretic and anti-inflammatory preparations, preparations for the treatment of arthritis, preparations having psychotherapeutic properties, preparations for treatment of cold, flu, cough, sinus, allergy, cardiovascular emergencies, neurological conditions, chronic pain management, and gastro-intestinal disorders; pharmaceutical preparations, namely, smoking cessation preparations, analgesic preparations, sleep aid-preparations, anti-pyretic and anti-inflammatory preparations, preparations for the treatment of arthritis, preparations having psychotherapeutic properties, preparations for treatment of cold, flu, cough, sinus, allergy, cardiovascular emergencies, neurological conditions, chronic pain management, and gastro-intestinal disorders in chewable form, in gum form, in lozenge form, and in pouch powder form; aerosolized and inhaled therapeutics and pharmaceuticals, namely, smoking cessation preparations, analgesic preparations, sleep aid-preparations, anti- pyretic and anti-inflammatory preparations, preparations for the treatment of arthritis, preparations having psychotherapeutic properties, preparations for treatment of cold, flu, cough, sinus, allergy, cardiovascular emergencies, neurological conditions, chronic pain management, and gastro-intestinal disorders; pharmaceutical preparations for inhalation, namely, smoking cessation preparations, analgesic preparations, sleep aid-preparations, anti-pyretic and anti-inflammatory preparations, preparations for the treatment of arthritis, preparations having psychotherapeutic properties, preparations for treatment of cold, flu, cough, sinus, allergy, cardiovascular emergencies, neurological conditions, chronic pain management, and gastro-intestinal disorders; drug delivery agents in the form of fast liquefiable tablets, compressed gum, extruded gum, lozenges, pouch powder, dissolvable films, coatings for tablets, and transdermal patches that facilitate the delivery of pharmaceutical preparations, namely, smoking cessation preparations, analgesic preparations, sleep aid-preparations, anti-pyretic and anti-inflammatory preparations, preparations for the treatment of arthritis, preparations having psychotherapeutic properties, preparations for treatment of cold, flu, cough, sinus, allergy, cardiovascular emergencies, neurological conditions, chronic pain management, and gastro-intestinal disorders; vitamins and dietary supplements; dietetic foodstuffs adapted for medical purposes; nicotine gum for use as an aid to stop smoking; medicated chewing gum as a drug delivery agent to facilitate the delivery of pharmaceutical preparations; dietetic preparations for medical use; herbal extracts for medical purposes; herbal teas for medicinal purposes Custom manufacture of pharmaceuticals and nutraceuticals; consultancy regarding the custom manufacture of pharmaceuticals and nutraceuticals; custom manufacture of pharmaceuticals, namely, formulation of pharmaceutical preparations for treatment of a wide variety of conditions in chewable form, in gum form, in lozenge form, and in pouch powder form; custom manufacture of pharmaceuticals, namely, formulation of inhaled therapeutics; custom manufacture of pharmaceuticals, namely, formulation of pharmaceuticals and well-being products for oral and intra-oral delivery systems; research, and development of pharmaceuticals and well-being products for oral and intra-oral delivery systems; custom manufacture of pharmaceuticals, namely, formulation of pharmaceuticals for smoking cessation; provision of advice, information and consultancy in relation to the aforesaid services Scientific, medical and technological services and research and design relating thereto namely, research and development of technology in the field of smoking cessation preparations, analgesic preparations, sleep aid-preparations, anti-pyretic and anti-inflammatory preparations, preparations for the treatment of arthritis, preparations having psychotherapeutic properties, preparations for treatment of cold, flu, cough, sinus, allergy, cardiovascular emergencies, neurological conditions, chronic pain management, and gastro-intestinal disorders; industrial analysis and industrial research services in the field of pharmaceutical research and development services; research, and development of pharmaceutical preparations for treatment of a wide variety of conditions in chewable form, in gum form, in lozenge form, and in pouch powder form; research and development of inhaled therapeutics; research, and development of pharmaceuticals and well-being products for oral and intra-oral delivery systems; research and development of pharmaceuticals for smoking cessation; provision of advice, information and consultancy in relation to the aforesaid service
The invention relates to an orally disintegrating nicotine tablet for nicotine craving relief comprising a pressed powder formulation, the tablet being designed to disintegrate within a period of less than 60 seconds upon oral administration, the powder formulation comprising an amount of nicotine and a pH regulating agent.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Pharmaceutical preparations for smoking cessation; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of insomnia and sleep disorders, and to improve quality and quantity of sleep; pharmaceutical preparations to treat fever; pharmaceutical preparations to treat inflammation; Pharmaceutical preparations for the treatment of arthritis; psychotherapeutic pharmaceutical preparations; pharmaceutical preparations for treatment of cold; Pharmaceutical preparations for treatment of flu; Pharmaceutical preparations for treatment of cough; Pharmaceutical preparations for treatment of sinus; Pharmaceutical preparations for treatment of allergy; Pharmaceutical preparations for treatment of cardiovascular diseases; Pharmaceutical preparations for treatment of neurological disorders; Pharmaceutical preparations for treatment of chronic pain; Pharmaceutical preparations for treatment of gastro-intestinal disorders; vitamins; dietary supplements prepared from fruit extracts; dietary supplements prepared from vegetable extracts; dietary supplements prepared from herbal extracts; dietetic supplements prepared from herbal extracts; dietetic supplements prepared from fruit extracts; dietetic supplements prepared from vegetable extracts; nicotine chewing gum for use as aid to stop smoking; medicated chewing gum; dietetic substances adapted for medical use; herbal extracts for medical purposes; herbal teas for medicinal purposes Custom manufacture of pharmaceuticals and nutraceuticals; consultancy regarding the custom manufacture of pharmaceuticals and nutraceuticals; provision of advice, information and consultancy in relation to the aforesaid services Research and development of technology in the field of smoking cessation preparations; research and development of technology in the field of analgesics; research and development of technology in the field of sleep aid drugs; research and development of technology in the field of anti-pyretic drugs; research and development of technology in the field of anti-inflammatory preparations; research and development of technology in the field of pharmaceutical preparations for the treatment of arthritis; research and development of technology in the field of psychotherapeutic preparations; research and development of technology in the field of pharmaceutical preparations for treatment of cold; research and development of technology in the field of pharmaceutical preparations for treatment of flu; research and development of technology in the field of pharmaceutical preparations for treatment of cough; research and development of technology in the field of pharmaceutical preparations for treatment of sinus; research and development of technology in the field of pharmaceutical preparations for treatment of allergy; research and development of technology in the field of pharmaceutical preparations for treatment of cardiovascular diseases; research and development of technology in the field of pharmaceutical preparations for treatment of neurological disorders; research and development of technology in the field of pharmaceutical preparations for treatment of chronic pain; research and development of technology in the field of pharmaceutical preparations for treatment of gastro-intestinal disorders; design of new products for others; scientific and technological services in the nature of testing of new products for others; medical research services; scientific research services; pharmaceutical products development; formulation of inhaled therapeutics; research and development of inhaled therapeutics; formulation of pharmaceuticals for oral and intra-oral delivery systems; research and development of pharmaceuticals for oral and intra-oral delivery systems
05 - Produits pharmaceutiques, vétérinaires et hygièniques
40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
(1) Pharmaceutical preparations; pharmaceutical preparations for treatment of a wide variety of diseases and conditions in chewable form, in gum form, in lozenge form, and in pouch powder form; pharmaceutical preparations for smoking cessation; aerosolized or inhaled therapeutics and pharmaceuticals; drug delivery agents in the form of fast liquefiable tablets, compressed gum, extruded gum, lozenges, pouch powder, dissolvable films, coatings for tablets, and transdermal patches that facilitate the delivery of pharmaceutical preparations; vitamins and dietary supplements; dietetic foodstuffs adapted for medical purposes; nicotine chewing gum; nicotine gum for use as an aid to stop smoking; medicated chewing gum; dietetic preparations for medical use; herbal extracts for medical purposes; herbal teas for medicinal purposes (1) Manufacture of pharmaceuticals and nutraceuticals; consultancy regarding the manufacture of pharmaceuticals and nutraceuticals; provision of advice, information and consultancy in relation to the aforesaid services
(2) Scientific, medical and technological services and research and design relating thereto; industrial analysis and industrial research services; pharmaceutical research and development; formulation, research, and development of pharmaceutical preparations for treatment of a wide variety of diseases and conditions in chewable form, in gum form, in lozenge form, and in pouch powder form; formulation, research, and development of inhaled therapeutics; formulation, research, and development of pharmaceutical and well-being products for oral and intra-oral delivery systems; formulation, research, and development of pharmaceuticals for smoking cessation; provision of advice, information and consultancy in relation to the aforesaid services
05 - Produits pharmaceutiques, vétérinaires et hygièniques
40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Pharmaceutical preparations; pharmaceutical preparations for treatment of a wide variety of diseases and conditions in chewable form, in gum form, in lozenge form, and in pouch powder form; pharmaceutical preparations for smoking cessation; aerosolized or inhaled therapeutics and pharmaceuticals; drug delivery agents in the form of fast liquefiable tablets, compressed gum, extruded gum, lozenges, pouch powder, dissolvable films, coatings for tablets, and transdermal patches that facilitate the delivery of pharmaceutical preparations; vitamins and dietary supplements; dietetic foodstuffs adapted for medical purposes; nicotine chewing gum; nicotine gum for use as an aid to stop smoking; medicated chewing gum; dietetic preparations for medical use; herbal extracts for medical purposes; herbal teas for medicinal purposes. Manufacture of pharmaceuticals and nutraceuticals; consultancy regarding the manufacture of pharmaceuticals and nutraceuticals; provision of advice, information and consultancy in relation to the aforesaid services. Scientific, medical and technological services and research and design relating thereto; industrial analysis and industrial research services; pharmaceutical research and development; formulation, research, and development of pharmaceutical preparations for treatment of a wide variety of diseases and conditions in chewable form, in gum form, in lozenge form, and in pouch powder form; formulation, research, and development of inhaled therapeutics; formulation, research, and development of pharmaceutical and well-being products for oral and intra-oral delivery systems; formulation, research, and development of pharmaceuticals for smoking cessation; provision of advice, information and consultancy in relation to the aforesaid services.
A water-dissolvable nicotine tablet is disclosed, the nicotine tablet comprising at least a first compressed module and a second compressed module, wherein the first compressed module is an FDT-module and comprises nicotine, alkaline pH regulating agent, and disintegrant, and, wherein the second compressed module is a lozenge-module and comprises acidic pH regulating agent. Also, a method of manufacturing a nicotine tablet is disclosed.
A water-dissolvable nicotine tablet is disclosed, the nicotine tablet comprising at least a first compressed module and a second compressed module, wherein the first compressed module is an FDT-module and comprises nicotine, alkaline pH regulating agent, and disintegrant, and, wherein the second compressed module is a lozenge-module and comprises acidic pH regulating agent. Also, a method of manufacturing a nicotine tablet is disclosed.
A61K 31/4439 - Pyridines non condensées; Leurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p.ex. oméprazole
A water-dissolvable nicotine tablet is disclosed, the nicotine tablet comprising at least a first compressed module and a second compressed module, wherein the first compressed module is an FDT-module and comprises nicotine, alkaline pH regulating agent, and disintegrant, and, wherein the second compressed module is a lozenge-module and comprises acidic pH regulating agent. Also, a method of manufacturing a nicotine tablet is disclosed.
A61K 31/20 - Acides carboxyliques, p.ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p.ex. acides stéarique, palmitique ou arachidique
A61K 31/375 - Acide ascorbique, c. à d. vitamine C; Ses sels
A61K 47/26 - Hydrates de carbone, p.ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharides; Leurs dérivés, p.ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/36 - Polysaccharides; Leurs dérivés, p.ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
The invention relates to an oral nicotine formulation for use in the alleviation of nicotine craving, the formulation comprising a content of nicotine and a content of a pH regulating agent, wherein the formulation provides a peak saliva concentration of nicotine of more than 0.3 mg/mL and a peak saliva pH of more than 7.5 during the first 120 seconds upon oral administration.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p.ex. poudres
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. carbomères
The invention relates to an oral chewable tablet suitable for improved mouthfeel, comprising dextrose in an amount from 50 to 95% by weight of the tablet; one or more active ingredients; and one or more binders, wherein the ratio between the one or more binders and dextrose is from 1:250 to 1:8.
The invention relates to an oral chewable tablet suitable for improved mouthfeel,comprising dextrose in an amount from 50 to 95% by weight of the tablet; one or more active ingredients; and one or more binders, wherein the ratio between the one or more binders and dextrose is from 1:250 to 1:8.
The present invention relates to an oral chewable tablet, comprising dextrose in an amount from 50 to 95% by weight of the tablet; and one or more active ingredients in an amount from 0.1 to 50% by weight of the tablet. The oral chewable tablet comprises at least two compressed layers containing said dextrose and the one or more active ingredients, the first of the compressed layers being cohered to and adjacent to the second layer.
The present invention relates to an oral chewable tablet, comprising dextrose in an amount from 50 to 95% by weight of the tablet; and one or more active ingredients in an amount from 0.1 to 50% by weight of the tablet. The oral chewable tablet comprises at least two compressed layers containing said dextrose and the one or more active ingredients, the first of the compressed layers being cohered to and adjacent to the second layer.
The invention relates to an oral chewable tablet suitable for improved mouthfeel, comprising dextrose in an amount from 50 to 95% by weight of the tablet; one or more active ingredients; and one or more binders, wherein the ratio between the one or more binders and dextrose is from 1:250 to 1:8.
A61K 47/26 - Hydrates de carbone, p.ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharides; Leurs dérivés, p.ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A23L 27/00 - ALIMENTS, PRODUITS ALIMENTAIRES OU BOISSONS NON ALCOOLISÉES NON COUVERTS PAR LES SOUS-CLASSES OU ; LEUR PRÉPARATION OU TRAITEMENT, p.ex. CUISSON, MODIFICATION DES QUALITÉS NUTRITIVES, TRAITEMENT PHYSIQUE ; CONSERVATION DES ALIMENTS OU PRODUITS ALIMENTAIRES EN GÉNÉRAL Édulcorants artificiels; Sels de table; Substituts diététiques du sel; Leur préparation ou leur traitement
A23L 29/00 - Aliments ou produits alimentaires contenant des additifs; Leur préparation ou leur traitement
A23P 10/20 - Agglomération; Granulation; Mise en comprimés
A solid oral nicotine formulation is disclosed, the formulation comprises a nicotine-ion exchange resin combination, and a salt comprising inorganic divalent cations, wherein the salt has a water-solubility of at least 5 grams per 100 mL of water measured at 25 degrees Celsius, atmospheric pressure and pH 7.0.
A61K 47/14 - Esters d’acides carboxyliques, p.ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/26 - Hydrates de carbone, p.ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharides; Leurs dérivés, p.ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. carbomères
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes ; Huiles, graisses ou cires naturelles ou naturelles modifiées, p.ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
A solid oral nicotine formulation is disclosed, the formulation comprises a nicotine- ion exchange resin combination, and a salt comprising inorganic divalent cations, wherein the salt has a water-solubility of at least 5 grams per 100 mL of water measured at 25 degrees Celsius, atmospheric pressure and pH 7Ø
A solid oral nicotine formulation is disclosed, the formulation comprises a nicotine- ion exchange resin combination, and a salt comprising inorganic divalent cations, wherein the salt has a water-solubility of at least 5 grams per 100 mL of water measured at 25 degrees Celsius, atmospheric pressure and pH 7.0.
The invention relates to oral analgesic compositions for alleviation of perceived nicotine irritation through inhibition or blocking of nicotine activated receptors or ion channels in the gastrointestinal tract, including the oral cavity. The composition of the invention comprises one or more nicotine sources, one or more buffering agents,5 and at least two antagonists in an effective amount to inhibit or block nicotine agonist activation of Nicotinic Acetylcholine Receptors (nAChR) and/or Transient Receptor Potential (TRP) ion channels, the at least two antagonists being selected from the group consisting of a first antagonist comprising camphor or one or more compounds resembling camphor, a second antagonist comprising eucalyptol, and a 10 third antagonist comprising (1R,2S,5R)-N-(4-Methoxyphenyl)-5-methyl-2-(1- methylethyl)cyclohexanecarboxamide (WS-12).
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/125 - Camphre; Ses dérivés substitués sur le cycle
A61K 31/167 - Amides, p.ex. acides hydroxamiques ayant des cycles aromatiques, p.ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p.ex. lidocaïne, paracétamol
The invention relates to oral analgesic compositions for alleviation of perceived nicotine irritation through inhibition or blocking of nicotine activated receptors or ion channels in the gastrointestinal tract, including the oral cavity. The composition of the invention comprises one or more nicotine sources, one or more buffering agents,5 and at least two antagonists in an effective amount to inhibit or block nicotine agonist activation of Nicotinic Acetylcholine Receptors (nAChR) and/or Transient Receptor Potential (TRP) ion channels, the at least two antagonists being selected from the group consisting of a first antagonist comprising camphor or one or more compounds resembling camphor, a second antagonist comprising eucalyptol, and a 10 third antagonist comprising (1R,2S,5R)-N-(4-Methoxyphenyl)-5-methyl-2-(1- methylethyl)cyclohexanecarboxamide (WS-12).
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/125 - Camphre; Ses dérivés substitués sur le cycle
A61K 31/167 - Amides, p.ex. acides hydroxamiques ayant des cycles aromatiques, p.ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p.ex. lidocaïne, paracétamol
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
67.
Oral Antagonist Compositions For Nicotine Burning Relief
The invention relates to oral analgesic compositions for alleviation of perceived nicotine irritation through inhibition or blocking of nicotine activated receptors or ion channels in the gastrointestinal tract, including the oral cavity. The composition of the invention comprises one or more nicotine sources, one or more buffering agents, and at least two antagonists in an effective amount to inhibit or block nicotine agonist activation of Nicotinic Acetylcholine Receptors (nAChR) and/or Transient Receptor Potential (TRP) ion channels, the at least two antagonists being selected from the group consisting of a first antagonist comprising camphor or one or more compounds resembling camphor, a second antagonist comprising eucalyptol, and a third antagonist comprising (1R,2S,5R)—N-(4-Methoxyphenyl)-5-methyl-2-(1-methylethyl)cyclohexanecarboxamide (WS-12).
A61K 31/125 - Camphre; Ses dérivés substitués sur le cycle
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p.ex. cannabinols, méthanthéline
A61K 31/167 - Amides, p.ex. acides hydroxamiques ayant des cycles aromatiques, p.ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p.ex. lidocaïne, paracétamol
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/26 - Hydrates de carbone, p.ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharides; Leurs dérivés, p.ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. carbomères
The invention relates to a flowpack for oral delivery of active ingredients comprising a population of particles and one or more active ingredients, the population of particles including at least two types of sugar alcohol particles, wherein at least one of said two types of sugar alcohol particles comprises i) granulated sugar alcohol particles.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p.ex. poudres
A61K 9/68 - Préparations médicinales caractérisées par un aspect particulier du type chewing-gum
A61K 47/26 - Hydrates de carbone, p.ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharides; Leurs dérivés, p.ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
The invention relates to a powder mixture for oral delivery of active ingredients, the powder mixture comprising a population of particles and one or more active ingredients, the population of particles including at least two types of sugar alcohol particles, wherein: at least one of said at least two types of sugar alcohol particles comprising i) non-directly compressible (non-DC) sugar alcohol particles or ii) directly compressible (DC) sugar alcohol particles that are not granulated sugar alcohol particles; at least one of said at least two types of sugar alcohol particles having a particle size with more than 50% of the particles being below 250 microns; and at least one of said at least two types of sugar alcohol particles being present in an amount of at least 20% by weight of the powder mixture.
A61K 47/26 - Hydrates de carbone, p.ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharides; Leurs dérivés, p.ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
A mouthwash and method for oral care benefits includes a swishable powder delivery system having a content of at least two types of sugar alcohol particles with different particle size distributions and one or more active ingredients, the powder delivery system being a dry and flowable population of particles suitable for resembling a liquid mouthwash by swishing the powder delivery system, thereby generating fluid in the oral cavity without adding water.
A61K 8/49 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques contenant des composés hétérocycliques
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/191 - Acides acycliques ayant plusieurs groupes hydroxyle, p.ex. acide gluconique
A61K 31/194 - Acides carboxyliques, p.ex. acide valproïque ayant plusieurs groupes carboxyle, p.ex. acides succinique, maléique ou phtalique
The invention relates to a mouthwash and method for oral care benefits comprising a swishable powder delivery system having a content of at least two types of sugar alcohol particles with different particle size distributions and one or more active ingredients, the powder delivery system being a dry and flowable population of particles suitable for resembling a liquid mouthwash by swishing said powder delivery system, thereby generating fluid in the oral cavity without adding water.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 9/68 - Préparations médicinales caractérisées par un aspect particulier du type chewing-gum
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p.ex. poudres
A61K 47/26 - Hydrates de carbone, p.ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharides; Leurs dérivés, p.ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 8/02 - Cosmétiques ou préparations similaires pour la toilette caractérisés par une forme physique particulière
A61K 8/49 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques contenant des composés hétérocycliques
A61K 8/92 - Huiles, graisses ou cires; Leurs dérivés, p.ex. produits d'hydrogénation
A61Q 11/00 - Préparations pour le nettoyage des dents, de la bouche ou des prothèses dentaires, p.ex. dentifrices; Bains de bouche
A61K 31/09 - Ethers ou acétals ayant une liaison éther à un carbone cyclique d'un noyau aromatique ayant plusieurs liaisons éther
A61K 31/135 - Amines, p.ex. amantadine ayant des cycles aromatiques, p.ex. méthadone
A61K 31/167 - Amides, p.ex. acides hydroxamiques ayant des cycles aromatiques, p.ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p.ex. lidocaïne, paracétamol
A61K 31/192 - Acides carboxyliques, p.ex. acide valproïque ayant des groupes aromatiques, p.ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 31/485 - Dérivés du morphinane, p.ex. morphine, codéine
The invention relates to a mouthwash and method for oral care benefits comprising a swishable powder delivery system having a content of at least two types of sugar alcohol particles with different particle size distributions and one or more active ingredients, the powder delivery system being a dry and flowable population of particles suitable for resembling a liquid mouthwash by swishing said powder delivery system, thereby generating fluid in the oral cavity without adding water.
A61K 8/49 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques contenant des composés hétérocycliques
A61K 8/92 - Huiles, graisses ou cires; Leurs dérivés, p.ex. produits d'hydrogénation
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p.ex. poudres
A61K 9/68 - Préparations médicinales caractérisées par un aspect particulier du type chewing-gum
A61K 31/09 - Ethers ou acétals ayant une liaison éther à un carbone cyclique d'un noyau aromatique ayant plusieurs liaisons éther
A61K 31/135 - Amines, p.ex. amantadine ayant des cycles aromatiques, p.ex. méthadone
A61K 31/167 - Amides, p.ex. acides hydroxamiques ayant des cycles aromatiques, p.ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p.ex. lidocaïne, paracétamol
A61K 31/192 - Acides carboxyliques, p.ex. acide valproïque ayant des groupes aromatiques, p.ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 31/485 - Dérivés du morphinane, p.ex. morphine, codéine
A61K 47/26 - Hydrates de carbone, p.ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharides; Leurs dérivés, p.ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61Q 11/00 - Préparations pour le nettoyage des dents, de la bouche ou des prothèses dentaires, p.ex. dentifrices; Bains de bouche
A powder mixture for oral delivery of active ingredients includes a population of particles and one or more active ingredients, the population of particles including at least two types of sugar alcohol particles. At least one of the at least two types of sugar alcohol particles takes the form of i) non-directly compressible (non-DC) sugar alcohol particles or ii) directly compressible (DC) sugar alcohol particles that are not granulated sugar alcohol particles. At least one of the at least two types of sugar alcohol particles has a particle size with more than 50% of the particles being below 250 microns, and at least one of the at least two types of sugar alcohol particles is present in an amount of at least 20% by weight of the powder mixture.
A61K 8/49 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques contenant des composés hétérocycliques
A flowpack for oral delivery of active ingredients comprises a population of particles and one or more active ingredients, the population of particles including at least two types of sugar alcohol particles, wherein at least one of said two types of sugar alcohol particles comprises granulated sugar alcohol particles.
The invention relates to a flowpack for oral delivery of active ingredients comprising a population of particles and one or more active ingredients, the population of particles including at least two types of sugar alcohol particles, wherein at least one of said two types of sugar alcohol particles comprises i) granulated sugar alcohol particles.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 9/68 - Préparations médicinales caractérisées par un aspect particulier du type chewing-gum
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p.ex. poudres
A61K 47/26 - Hydrates de carbone, p.ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharides; Leurs dérivés, p.ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
The invention relates to a powder mixture for oral delivery of active ingredients, the powder mixture comprising a population of particles and one or more active ingredients, the population of particles including at least two types of sugar alcohol particles, wherein: at least one of said at least two types of sugar alcohol particles comprising i) non-directly compressible (non-DC) sugar alcohol particles or ii) directly compressible (DC) sugar alcohol particles that are not granulated sugar alcohol particles; at least one of said at least two types of sugar alcohol particles having a particle size with more than 50% of the particles being below 250 microns; and at least one of said at least two types of sugar alcohol particles being present in an amount of at least 20% by weight of the powder mixture.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p.ex. poudres
A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
A61K 47/26 - Hydrates de carbone, p.ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharides; Leurs dérivés, p.ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
A61K 36/00 - Préparations médicinales de constitution indéterminée contenant du matériel provenant d'algues, de lichens, de champignons, ou de plantes, ou leurs dérivés, p.ex. médicaments traditionnels à base de plantes
An oral tablet for delivery of active ingredients to the gastrointestinal tract includes a population of particles and an active ingredient to be delivered to the gastrointestinal tract. The population of particles includes directly compressible (DC) and non-directly compressible (non-DC) sugar alcohol particles, the non-DC particles providing the tablet with a plurality of discrete non-DC areas, and the non-DC areas resulting in induced saliva generation upon mastication of the tablet, wherein the tablet is designed to be masticated and designed to deliver the active ingredient to the gastrointestinal tract as part of the saliva generated upon mastication of the tablet.
A61K 31/165 - Amides, p.ex. acides hydroxamiques ayant des cycles aromatiques, p.ex. colchicine, aténolol, progabide
A61K 31/43 - Composés contenant des systèmes cycliques thia-4 aza-1 bicyclo [3.2.0] heptane, c.à d. composés contenant un système cyclique de formule , p.ex. pénicillines, pénèmes
A61K 31/606 - Acide salicylique; Ses dérivés ayant des groupes amino
A61K 31/708 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p.ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p.ex. adénosine, acide adénylique ayant des groupes oxo liés directement au système cyclique purine, p.ex. guanosine, acide guanylique
78.
Oral tablet for taste masking of active ingredients
An oral tablet for taste masking of active ingredients includes a population of particles and an active ingredient with off-note taste. The population of particles includes directly compressible (DC) and non-directly compressible (non-DC) sugar alcohol particles, the non-DC particles providing the tablet with a plurality of discrete non-DC areas, and the non-DC areas resulting at least partly in induced taste masking of the active ingredient upon mastication of the tablet.
A disintegrating oral tablet suitable for active pharmaceutical ingredients includes a population of particles and at least one flavor ingredient. The population of particles includes directly compressible (DC) and non-directly compressible (non-DC) sugar alcohol particles, the non-DC particles providing the tablet with a plurality of discrete non-DC areas, and the non-DC areas resulting in a burst of the at least one flavor ingredient upon mastication of the tablet.
The invention relates to a solid pharmaceutical tablet for oral delivery, the tablet comprising calcium carbonate in an amount of more than 30% by weight of the tablet and organic water-insoluble components in an amount of more than 20% by weight of the tablet, wherein the tablet is designed to be masticated into a coherent residual containing the organic water-insoluble components, and wherein the tablet is adapted to release more than 80% of the calcium carbonate within 5 minutes of mastication.
A61K 31/192 - Acides carboxyliques, p.ex. acide valproïque ayant des groupes aromatiques, p.ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 9/68 - Préparations médicinales caractérisées par un aspect particulier du type chewing-gum
A61K 31/167 - Amides, p.ex. acides hydroxamiques ayant des cycles aromatiques, p.ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p.ex. lidocaïne, paracétamol
81.
Tablet dosage form for buccal absorption of active ingredients
The invention relates to a tablet dosage form for buccal absorption of active ingredients comprising a population of particles and an active ingredient to be released in the oral cavity for absorption through the oral mucosa, the population of particles comprising directly compressible (DC) and non-directly compressible (non-DC) sugar alcohol particles, the non-DC particles providing the tablet with a plurality of discrete non-DC areas.
The present invention relates to an oral tablet for oromucosal delivery of biologically active compounds, the tablet comprising a sugar alcohol composition comprising one or more sugar alcohol particles in an amount of at least 20% by weight of the tablet, an ion-exchange composition comprising a plurality of particles of at least one water- soluble anionic mucoadhesive polymer loaded with a cationic biologically active compound.
A water-dissolvable compressed oral nicotine lozenge is disclosed, the oral nicotine lozenge comprising a first module and a second module, the first and the second modules being fused by compression, the first module being a lozenge module comprising at least one sugar alcohol and the second module being an FDT-module comprising at least one sugar alcohol and nicotine. Also, a method of manufacturing a water-dissolvable compressed oral nicotine lozenge is disclosed.
A water-dissolvable compressed oral nicotine lozenge is disclosed, the oral nicotine lozenge comprising a first module and a second module, the first and the second modules being fused by compression, the first module being a lozenge module comprising at least one sugar alcohol and the second module being an FDT-module comprising at least one sugar alcohol and nicotine. Also, a method of manufacturing a water-dissolvable compressed oral nicotine lozenge is disclosed.
A61K 47/26 - Hydrates de carbone, p.ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharides; Leurs dérivés, p.ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. carbomères
85.
Ion-Exchange Composition With Water-Soluble Mucoadhesive Polymers
The present invention relates to an oral tablet for oromucosal delivery of biologically active compounds, the tablet comprising a sugar alcohol composition comprising one or more sugar alcohol particles in an amount of at least 20% by weight of the tablet, an ion-exchange composition comprising a plurality of particles of at least one water-soluble anionic mucoadhesive polymer loaded with a cationic biologically active compound.
The invention relates to a disintegrating oral tablet suitable for active pharmaceutical ingredients comprising a population of particles and at least one flavor ingredient, the population of particles comprising directly compressible (DC) and non-directly compressible (non-DC) sugar alcohol particles, the non-DC particles providing the tablet with a plurality of discrete non-DC areas, and
The invention relates to a disintegrating oral tablet suitable for active pharmaceutical ingredients comprising a population of particles and at least one flavor ingredient, the population of particles comprising directly compressible (DC) and non-directly compressible (non-DC) sugar alcohol particles, the non-DC particles providing the tablet with a plurality of discrete non-DC areas, and
the non-DC areas resulting in a burst of the at least one flavor ingredient upon mastication of the tablet.
A water-dissolvable compressed oral nicotine lozenge is disclosed, the oral nicotine lozenge comprising a first module and a second module, the first and the second modules being fused by compression, the first module being a lozenge module comprising at least one sugar alcohol and the second module being an FDT-module comprising at least one sugar alcohol and nicotine. Also, a method of manufacturing a water-dissolvable compressed oral nicotine lozenge is disclosed.
The present invention relates to an oral tablet for oromucosal delivery of biologically active compounds, the tablet comprising a sugar alcohol composition comprising one or more sugar alcohol particles in an amount of at least 20% by weight of the tablet, an ion-exchange composition comprising a plurality of particles of at least one water- soluble anionic mucoadhesive polymer loaded with a cationic biologically active compound.
The invention relates to a solid pharmaceutical tablet for oral delivery, the tablet comprising calcium carbonate in an amount of more than 30% by weight of the tablet and organic water-insoluble components in an amount of more than 20% by weight of the tablet, wherein the tablet is designed to be masticated into a coherent residual containing the organic water-insoluble components, and wherein the tablet is adapted to release more than 80% of the calcium carbonate within 5 minutes of mastication.
A61K 31/192 - Acides carboxyliques, p.ex. acide valproïque ayant des groupes aromatiques, p.ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 9/68 - Préparations médicinales caractérisées par un aspect particulier du type chewing-gum
A61K 31/167 - Amides, p.ex. acides hydroxamiques ayant des cycles aromatiques, p.ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p.ex. lidocaïne, paracétamol
03 - Produits cosmétiques et préparations de toilette; préparations pour blanchir, nettoyer, polir et abraser.
30 - Aliments de base, thé, café, pâtisseries et confiseries
Produits et services
Cleaning, polishing, scouring and abrasive preparations. Bubble gum; Breath-freshening chewing gum; Lozenges; Confectionery, including pastilles [confectionery]; Peppermint candy; Breath mints for use as a breath freshener.
03 - Produits cosmétiques et préparations de toilette; préparations pour blanchir, nettoyer, polir et abraser.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
30 - Aliments de base, thé, café, pâtisseries et confiseries
Produits et services
Breath freshening preparations for personal hygiene; Mouthwashes, not for medical purposes; Tooth whitening preparations; Cleaning, polishing, scouring and abrasive preparations; Dental products, including toothpastes, mouthwashes and cosmetic preparations for oral care (not for medical purposes); Breath fresheners. Acetates for pharmaceutical purposes; Acids for pharmaceutical purposes; Alginate dietary supplements; Dietary and nutritional supplements; Dietary supplements and dietetic preparations; Alginates for pharmaceutical purposes; Analgesics; Appetite suppressant pills; Astringents for medical purposes; Bacterial preparations for medical and veterinary use; Bacteriological preparations for medical and veterinary use; Biological preparations for medical purposes; Bronchodilating preparations; Camphor for medical purposes; Medicated candy; Candy for medical purposes; Chemical preparations for pharmaceutical use for the treatment of pain, indigestion, cough and colds, allergy symptoms, sleep problems, relaxation problems, weight control, energy deficiency and oral health problems; Chemical preparations for medicinal purposes for the treatment of pain, indigestion, cough and colds, allergy symptoms, sleep problems, relaxation problems, weight control, energy deficiency and oral health problems; Chewing gum for medical purposes; Dental abrasives; Dental mastics; Dietary fibre for the treatment of constipation; Dietary fiber to aid digestion; Dietary supplements for animals; Dietary supplements with a cosmetic effect; Dietetic foods adapted for medical use; Dietetic beverages adapted for medical purposes; Dietetic infusions for medical use; Digestives for pharmaceutical purposes; Disinfectants; Drugs for medicinal purposes for the treatment of pain, indigestion, cough and colds, allergy symptoms, sleep problems, relaxation problems, weight control, energy deficiency and oral health problems; Enzyme dietary supplements; Enzymes for medical purposes; Fungicides; Gum for medical purposes; Laxatives; Medical preparation for slimming purposes; Beverages adapted for medicinal purposes; Constipation (Medicines for alleviating -); Medicines for dental purposes; Medicine for human use for the treatment of pain, indigestion, cough and colds, allergy symptoms, sleep problems, relaxation problems, weight control, energy deficiency and oral health problems; Mint for pharmaceutical purposes; Mouthwashes for medical purposes; Nicotine gum for use as an aid to stop smoking; Nicotine patches for use as aids to stop smoking; Nutritional preparations for therapeutic or medicinal purposes for the treatment of pain, indigestion, cough and colds, allergy symptoms, sleep problems, relaxation problems, weight control, energy deficiency and oral health problems; Nutritional supplements; nutritive substances for microorganisms for medical purposes; Lozenges for pharmaceutical purposes; Throat lozenges for pharmaceutical purposes; Pharmaceutical preparations for the treatment of pain, indigestion, cough and colds, allergy symptoms, sleep problems, relaxation problems, weight control, energy deficiency and oral health problems; Pharmaceuticals for the treatment of pain, indigestion, cough and colds, allergy symptoms, sleep problems, relaxation problems, weight control, energy deficiency and oral health problems; Salts for medical purposes; Tranquillizers; Tranquillizers; slimming pills, slimming preparation for medical purposes; Sugar for medical purposes; Tonics (medicinal) for the treatment of pain, indigestion, cough and colds, allergy symptoms, sleep problems, relaxation problems, weight control, energy deficiency and oral health problems; Vitamin preparations; Vitamin tablets; Medicated lozenges; Medicated cough drops; Vitamin supplements; Medicated mouthwash; Mouthwashes for the prevention of caries; Medicated anti-cavity mouthwashes; Antiseptic mouthwashes; Antiseptic mouthwashes for cleansing; Antimicrobial mouthwashes; Dietary supplements, medicated confectionery, including medicated chewing gum. Bubble gum; Breath-freshening chewing gum; Lozenges; Confectionery, including pastilles [confectionery]; Peppermint candy; Breath mints for use as a breath freshener.
The invention relates an oral delivery vehicle tablet containing nicotine, the delivery vehicle tablet being formed by compression of a plurality of particles, the oral delivery vehicle tablet comprising nicotine, the oral delivery vehicle tablet comprising sugar alcohol(s) in an amount of 40 to 100% by weight of the delivery vehicle tablet, wherein at least 10% by weight of the delivery vehicle tablet comprises a plurality of particles consisting of erythritol and wherein the delivery vehicle tablet comprises a plurality of further sugar alcohol particles in an amount of at least 10% by weight of the delivery vehicle tablet, wherein said further sugar alcohol particles comprise at least one sugar alcohol and wherein said further sugar alcohols particles have a composition which is different from said particles consisting of erythritol.
The invention relates to an oral delivery vehicle tablet, the delivery vehicle tablet being formed by compression of a plurality of particles, wherein the oral delivery vehicle tablet comprises sugar alcohol(s) in an amount of 40 to 99.9% by weight of the delivery vehicle tablet, wherein the oral delivery vehicle tablet comprises non-direct compressible (non-DC) erythritol particles in an amount of 15-50% by weight of the delivery vehicle tablet, wherein the oral delivery vehicle tablet comprises one or more binders other than binders granulated to the sugar alcohol(s) in an amount of 0.1 to 6% by weight of the tablet, wherein the delivery vehicle tablet comprises a plurality of further sugar alcohol particles in an amount of at least 10% by weight of the delivery vehicle tablet and wherein said further sugar alcohols particles have a composition which is different from said non-DC erythritol.
The invention relates to a tableted chewing gum suitable for active pharmaceutical ingredients, the chewing gum comprising a population of particles, the population of particles comprising a) directly compressible (DC) sugar alcohol particles, b) non-directly compressible (non-DC) sugar alcohol particles and c) particles comprising gum base, the gum base comprising at least 5% by weight of elastomer.
The invention relates to a disintegrating oral tablet suitable for active pharmaceutical ingredients comprising a population of particles and at least one flavor ingredient, the population of particles comprising directly compressible (DC) and non-directly compressible (non-DC) sugar alcohol particles, the non-DC particles providing the tablet with a plurality of discrete non-DC areas, and the non-DC areas resulting in a burst of the at least one flavor ingredient upon mastication of the tablet.
The invention relates to an oral tablet for delivery of active ingredients to the throat comprising a population of particles and an active ingredient to be delivered to the throat, the population of particles comprising directly compressible (DC) and non-directly compressible (non-DC) sugar alcohol particles, the non-DC particles providing the tablet with a plurality of discrete non-DC areas, the non-DC areas resulting in induced saliva generation upon mastication of the tablet, wherein the tablet is designed to be masticated and designed to deliver the active ingredient to the throat as part of the saliva generated upon mastication of the tablet.
A61K 9/68 - Préparations médicinales caractérisées par un aspect particulier du type chewing-gum
A61K 31/455 - Acide nicotinique, c. à d. niacine; Ses dérivés, p.ex. esters, amides
A61K 47/26 - Hydrates de carbone, p.ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharides; Leurs dérivés, p.ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
97.
AN ORAL TABLET FOR DELIVERY OF ACTIVE INGREDIENTS TO THE GASTROINTESTINAL TRACT
The invention relates to an oral tablet for delivery of active ingredients to the gastrointestinal tract comprising a population of particles and an active ingredient to be delivered to the gastrointestinal tract, the population of particles comprising directly compressible (DC) and non-directly compressible (non-DC) sugar alcohol particles, the non-DC particles providing the tablet with a plurality of discrete non-DC areas, and the non-DC areas resulting in induced saliva generation upon mastication of the tablet, wherein the tablet is designed to be masticated and designed to deliver the active ingredient to the gastrointestinal tract as part of the saliva generated upon mastication of the tablet.
The invention relates to a tablet dosage form for buccal absorption of active ingredients comprising a population of particles and an active ingredient to be released in the oral cavity for absorption through the oral mucosa, the population of particles comprising directly compressible (DC) and non-directly compressible (non-DC) sugar alcohol particles, the non-DC particles providing the tablet with a plurality of discrete non-DC areas.
The invention relates to an oral tablet for taste masking of active ingredients, the tablet comprising a population of particles and an active ingredient with off-note taste, the population of particles comprising directly compressible (DC) and non-directly compressible (non-DC) sugar alcohol particles, the non-DC particles providing the tablet with a plurality of discrete non-DC areas, and the non-DC areas resulting at least partly in induced taste masking of the active ingredient upon mastication of the tablet.
